December 16, 2017 FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML
Read More
October 17, 2017 Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas
Read More
October 7, 2017 Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read More
October 3, 2017 Selvita and Menarini present together at the European Business Development Conference
Read More
August 8, 2017 Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients
Read More
July 13, 2017 Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project
Read More
June 6, 2017 Selvita presents at 18th Drug Discovery Summit in Berlin
Read More
April 7, 2017 Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget
Read More
March 28, 2017 Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24
Read More
March 17, 2017 Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read More
Posts navigation
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok Privacy policy 